US 11,783,366 B2
Combination therapies
Gordon Bray, San Francisco, CA (US); and Iris Chan, San Francisco, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Aug. 9, 2021, as Appl. No. 17/444,691.
Application 17/444,691 is a continuation of application No. 13/967,782, filed on Aug. 15, 2013, granted, now 11,087,354.
Claims priority of provisional application 61/780,708, filed on Mar. 13, 2013.
Claims priority of provisional application 61/722,725, filed on Nov. 5, 2012.
Claims priority of provisional application 61/706,026, filed on Sep. 26, 2012.
Claims priority of provisional application 61/705,575, filed on Sep. 25, 2012.
Claims priority of provisional application 61/684,673, filed on Aug. 17, 2012.
Prior Publication US 2022/0172244 A1, Jun. 2, 2022
Int. Cl. A61K 31/397 (2006.01); A61K 31/375 (2006.01); A61P 17/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); G06Q 30/0241 (2023.01); A61K 31/437 (2006.01); C12Q 1/6886 (2018.01); A61K 31/4523 (2006.01)
CPC G06Q 30/0241 (2013.01) [A61K 31/437 (2013.01); A61K 31/4523 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01)] 15 Claims
 
1. A method for extending duration of response to treatment in a patient having BRAFV600 mutation-positive unresectable or metastatic melanoma comprising administering to the patient (i) a first composition comprising [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]methanone, or a pharmaceutically acceptable salt thereof, at a dose of 60 mg on days 1-21 of a 28 day cycle; and (ii) a second composition comprising propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, at a dose of 960 mg twice daily on each day of the 28 day cycle.